Healthcare Industry News: Teva Pharma
News Release - October 11, 2006
Aero Pharm Acquires Baker Cummins(TM) Dermatology Products and U.S. Rights to Three Additional Dermatology Products from IVAX
BOCA RATON, Fla., Oct. 11 (HSMN NewsFeed) -- Aero Pharmaceuticals, Inc., a specialty pharmaceutical company focused on niche pharmaceuticals, announced that it has acquired the entire line of Baker Cummins(TM) over-the-counter (OTC) dermatology products as well as U.S. rights to additional dermatology products from IVAX Laboratories, Inc., a subsidiary of Teva Pharmaceuticals USA Inc.In addition to the Baker Cummins(TM) OTC dermatology products, which include P&S® Liquid, P&S® Shampoo, Ultra Mide 25® Lotion, X-Seb T® Pearl Shampoo, X-Seb T® Plus Shampoo and Aquaderm Cream, the acquisition includes the rights to distribute, market and sell, in the United States and its territories, Heliocare® Capsules, a patented dietary supplement for the skin, and UltraLytic® 2 Foam and Cream, which are prescription products indicated for softening and removing rough hyperkeratotic skin.
"We were delighted to have been selected as the commercial partner for IVAX back in early February 2006 and to have had the privilege to launch three new products on their behalf. The Aero dermatology sales force has been promoting these products to dermatologists since that initial launch," said Rick Aloi, president and CEO of Aero. "We are now equally delighted to acquire Heliocare® Capsules, UltraLytic® 2 Foam and Cream rights for the U.S. and the entire line of medicated shampoos and creams included in the Baker Cummins(TM) product line. This acquisition clearly supports Aero Pharm's specialty pharmaceutical strategy and positions Aero with unique and exclusive products."
Aero Pharmaceutical, Inc., headquartered in Boca Raton, Florida, is a specialty pharmaceuticals company that acquires, licenses in and markets and sells branded pharmaceuticals in the U.S. and its territories.
Source: Aero Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
